Similarly the risk/ benefit of continued Rapamune therapy should be re-evaluated in patients with severe refractory hyperlipidemia.
Samamoodi tuleb hinnata riski ja kasu vahekorda Rapamune’ ga ravi jätkamisel patsientidel, kellel on raskekujuline refraktaarne hüperlipideemia.